drugset
drugset / Trial / NCT04610138

Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants

NCT04610138 ↗

Phase 2 Completed 296 enrolled Clene Nanomedicine Azidus Brazil · collabICL Pharma · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multi-site, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of ZnAg liquid solution in symptomatic participants with acute COVID-19 that are not hospitalized at the time of enrollment.

Timeline

Start
2021-06-01
Primary completion
2022-05-28
Completion
2022-10-20

Drugs

EvaluationDrugModalityDoseRoute
Subject CNM-ZnAg Unknown 60 ml Oral

Indications

COVID-19